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Abstract  
Microvascular pericytes and the more recently discovered adventitial pericyte-like progenitor 
cells are a subpopulation of vascular stem cells closely associated with small and large blood 
vessels respectively. These populations of perivascular cells are remarkably abundant in the 
heart. Pericytes control important physiological processes such as angiogenesis, blood flow 
and vascular permeability. In the heart, this pleiotropic activity makes pericytes extremely 
interesting for applications in regenerative medicine. On the other hand, dysfunction of 
pericytes could participate in the pathogenesis of cardiovascular disease, such as arterial 
hypertension, fibro-calcific cardiovascular remodeling, myocardial edema and post-ischemic 
coronary no-reflow. On a therapeutic standpoint, preclinical studies in small animal models of 
myocardial infarction have demonstrated the healing potential of pericytes transplantation, 
which has been ascribed to direct vascular incorporation and paracrine pro-angiogenic and 
anti-apoptotic activities. These promising findings open the door to the clinical use of 
pericytes for the treatment of cardiovascular diseases. 
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1. Introduction 
 
The heart is a complex organ and multiple classes of stem cells with different potential and 
lineage commitment are necessary to ensure the physiologic turnover of cells over time and 
contribute to the repair of the organ in case of injury. Endothelial cells (ECs) are the most 
frequent cell type into the heart, followed by cardiomyocytes [1]. So far, resident cardiac stem 
cells residing in myocardial niches have been extensively studied and used in animal models 
of cardiac diseases thanks to their supposed capacity to generate all the mature cell types 
forming the heart, from cardiomyocytes to vascular mural and endothelial cells. However, at 
the aim of achieving the revascularization of ischemic areas of myocardium, specialized cells 
able to promote both the phenomena of vasculogenesis (the formation of new vessels starting 
from a primitive cell) and angiogenesis (sprouting of new capillaries off of existing vessels 
through recruitment of new vascular cells) might represent the ideal candidates. Recently, the 
discovery of multipotent stem cells in the vasculogenic niche of blood vessels has opened 
new perspectives for cardiovascular regenerative therapies.   
The vascular wall of small and large blood vessels is composed of different cell types with 
specialized functions, organized in concentric layers (Fig 1). In all vessels, ECs line the 
luminal side in contact with the bloodstream, forming the so called tunica intima; among ECs 
functions, there are the regulation of vascular permeability and hemostasis, the control of the 
vascular tone and the recruitment and homing of leukocytes. Smooth muscle cells (SMCs) 
populate the central layer in small and big arteries, the tunica media; their major functions are 
the regulation of vessel contractility and the synthesis of new extracellular matrix. Finally, 
fibroblasts and other stromal cells give rise to the external layer of large vessels, the tunica 
adventitia, and their major function is the production of extracellular matrix (ECM) 
components. Importantly, the tunica adventitia has been recognized as a reservoir of vascular 
stem/progenitor cells, spatially organized in a specialized microenvironment, namely the 
vasculogenic niche. 
Vascular stem cells (VSCs) are defined as multipotent cells residing within the blood vessels 
wall, or closely associated with the outmost layer of vessels, able to differentiate into all the 
cell types forming a mature functional vessel [2]. They are distributed along the entire 
vascular system, and their main functions are the maintenance of vessels integrity and the 
regulation of postnatal vasculogenesis. Based on the antigenic properties and differentiation 
capacity, VSCs are divided in four major populations: mesenchymal stem cells (MSCs), 
endothelial progenitor cells (EPCs), smooth muscle progenitors cells (SMPCs) and 
perivascular cells, that are microvascular pericytes and adventitial pericyte-like progenitors 
(Fig 1) [3, 4]. MSCs, EPCs and SMPCs reside in the inner part of the tunica adventitia called 
vasculogenic zone, and in addition EPCs have been observed in the subendothelial layer at the 
interphase between the tunica intima and media of large vessels [5-8]. Instead perivascular 
cells can be found both within the vasculogenic zone but also around blood microvessels (see 
chapter 2). Noteworthy, despite the general definition given to VSCs, the differentiation 
potential varies among the cells, and not all VSCs are indeed able to generate all the cell types 
forming a blood vessel.  
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Figure 1: Vascular stem cells distribution in the vascular system. Cartoon showing the structure of 
capillaries and large vessels, and the localization of the different populations of vascular stem cells. 
Abbreviations: MSCs, mesenchymal stem cells; EPCs, endothelial progenitor cells; SMCPs, smooth muscle 
cell progenitors; ECs, endothelial cells; SMCs, smooth muscle cells.  
 
 
This review will firstly introduce perivascular cells, also known as pericytes, reporting on 
their phenotype, classification and function; also, it will implement the classical concept of 
pericyte reporting on the new populations of adventitial pericyte-like cells recently described 
in large vessels. Secondly, it will focus on the heart and on cardiac pericytes (CPs), a 
population of cells with pleiotropic functions and whose role is gaining increasing importance 
in many biological processes. In particular, we will report on the dual and contrasting 
function of CPs, showing how they ensure the homeostasis of the organ in physiological 
conditions, while a perturbation of this state is reflected in cell dysfunction and the following 
contribution to cardiac pathologies, above all ischemic disease. In addition, we will show the 
promising therapeutic potential of pericytes derived from different sources – not only the 
heart – in in vivo preclinical studies for the treatment of ischemic heart disease.  
2. Perivascular cells 
Perivascular cells, commonly known with the name of pericytes, are a wide population 
phenotypically, biochemically and functionally heterogeneous. Their name derives from the 
peculiar localization surrounding and encircling endothelial cells of small blood vessels (peri, 
around; cyto, cell or vessel), where pericytes have been first identified.  
While it was originally believed that the only role of pericytes was to support ECs 
contributing at the stabilization of existing blood vessels and promoting angiogenesis, 
recently pericytes have been reconsidered as important players in a series of biological 
processes, such as pathogenesis, regeneration and repair.  
  6 
The concept of pericyte still represents an object of debate for Scientists. Originally, the 
microvascular pericyte has been defined as a cell encircling endothelial cells in capillaries 
and microvessels of most organs - excluded lymphatic vessels. However, in recent years, the 
discovery of cells with pericyte-like properties in the large vessels wall has challenged the 
unicity of the primitive concept, opening the way to a new population that here we name as 
adventitial pericyte-like progenitors (APs). These cells have been localized within the tunica 
adventitia of large vessels, sometimes associated with the vasa vasorum (nutritive 
microvessels in big veins and arteries) [9-12] (Fig 1). Experimental evidences collected so far 
indicate that classical microvascular pericytes and APs might be considered stem cells 
because, similarly to MSCs, they are highly proliferative and clonogenic, express stemness 
markers and, importantly, they are endowed with capability of multilineage differentiation in 
vitro [13]. Proof of their multipotency is the myogenic [14, 15], neurogenic [16] and 
vasculogenic [9] potential, reflecting the peculiarity of the tissue of origin. In addition, 
because of their wide differentiation potential, pericytes have been considered the ancestors of 
MSCs [13]. 
To date, the relation between microvascular pericytes and APs has not been clarified yet. 
Although sharing similar phenotype and functional properties, pericytes and APs are 
characterized by different biological properties (see below). There is still a huge non-
uniformity of opinion in describing and characterizing pericytes in different organs. In 
addition, the distinction between pericytes and MSCs or SMCs remains hard due to the high 
antigenic similarity. In the future, a general consensus similarly to what has been done for 
MSCs could help overcoming the current dilemma on how to establish the different identity 
of various cell populations sharing pericyte characteristics.  
Multiple populations of pericytes and APs have been identified and characterized by several 
Authors in different human vessels and tissues, among which there are the saphenous vein 
[11], the skeletal muscle [14], the heart [9, 15], the adipose tissue [10], the retina [17], the 
bone marrow (reticular cells) [18] and the brain [16]. Also, specialized pericytes have been 
named as hepatic stellate cells or Ito cells in the liver [19] and mesangial cells in the kidney 
glomerulus [20]. 
2.1 The microvascular pericyte 
Microvascular pericytes are contractile cells that support blood vessels by direct physical 
contacts with ECs and by release of paracrine molecular factors; they are placed under the 
basement membrane in close contact with ECs. Pericytes are characterized by multiple 
elongated cellular processes that wrap vessels; they communicate with neighboring ECs or 
other pericytes through peg-socket, gap and tight junctions [21-23]. Morphologically, in situ 
they are described like stellate cells with multiple cell processes encompassing the blood 
vessels. In the brain, the absence of pericytes leads to EC hyperplasia and abnormal structure, 
increase in vascular permeability and leakage, finally leading to hemorrhagic complications 
[24, 25], proof of a crucial contribution for pericytes in vascular homeostasis.  
Microvascular pericytes have been extensively characterized thanks to the wide abundance 
around capillaries perfusing all the districts of the body. Their density around blood 
microvessels is highly variable depending on the organ and vascular bed; according to few 
single reports in the literature, the vasculature of the central nervous system and the retina is 
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characterized by the highest ratio pericytes to ECs (1:1), while in other tissues this density is 
definitely decreased (1:100 in the striated skeletal muscle) [26, 27].  
Several important functions are known for microvascular pericytes, with specific functions 
developed based on the need of the organ in which they reside. On the one side, thanks to 
receptors for a large number of vasoactive signaling molecules, they control vascular caliber 
and tone and regulate vessel integrity and permeability; moreover, they support angiogenesis 
and EC differentiation and proliferation, produce extracellular matrix components and 
participate to the immune modulation [21, 22, 28]. On the other side, however, microvascular 
pericytes might also play a negative role promoting the occurrence of diseases; for example 
differentiation into myofibroblasts can implement a pro-fibrotic mechanism in organs like the 
muscles, the liver and the kidney [29, 30], while in the brain the release of pro-inflammatory 
factors by pericytes can activate microglial cells, finally resulting in neuro-inflammation [31].  
Most of microvascular pericytes, independently from the different sources, share in vivo and 
in ex vivo cultures a common antigenic profile; this is given by several markers between 
CD44, CD73, CD90, CD105, platelet-derived growth factor receptor- (PDGFR-), 
neural/glial antigen 2 (NG2), desmin, vimentin, regulator of G-protein signaling 5, alkaline 
phosphatase (ALP) and stromal precursor antigen-1 [13, 21, 22, 32]. The expression of 
transcription factors proper of a multipotency or stemness state such as octamer-binding 
transcription factor 4 (OCT4), homeobox NANOG (NANOG) and (sex determining region 
Y)-box 2 (SOX2) has been occasionally documented [9, 11]. However, some discrepancies 
have been reported when describing pericytes from different Investigators, even within the 
same organ. In particular, the expression of the markers CD34 and CD146 distinguishes two 
different big populations of microvascular pericytes. One of them is characterized by a 
phenotype CD146/NG2pos, CD34/CD31/CD45neg [15], while the other one is described as 
CD34/NG2pos, CD146/CD31/CD45neg [9, 11]. This evidence underlines once again the huge 
heterogeneity of microvascular pericytes. Finally, microvascular pericytes do not express 
typical endothelial markers such as CD31 and von Willebrand Factor, and hematopoietic 
markers such as CD45. 
2.2 The adventitial pericyte-like progenitor  
The interest in APs has risen only recently, for this reason these cells have been less 
characterized then the microvascular counterpart. APs have been identified in the adventitia 
of the saphenous vein, myocardial vessels, internal thoracic artery, thoracic aorta and 
arteries/veins from other tissues, and described as CD34pos but CD146/CD31/CD45neg cells 
[9-11]. Markers like CD105, CD44, CD90, NG2 and PDGFR- complete the phenotype of 
these pericyte-like cells.  
Transplantation in small animals has confirmed that APs derived from the human saphenous 
vein are endowed with the characteristics of pericytes, given they re-assume a perivascular 
position and establish direct contacts with ECs [11, 33]. Although the specific role for APs 
has not been totally clarified yet, Scientists have hypothesized these cells would represent the 
real vascular stem cells, behaving like primitive cells whose main role is to act as progenitors 
for the generation of other more specialized cell types, including MSCs [8, 10, 13]. Therefore, 
APs would represent a functionally different and more primitive population than 
microvascular pericytes. Data in support of the “stemness hypothesis” is the evidence that 
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CD34pos, CD31/CD146neg APs are multipotent at the clonal level, reason why they have been 
recognized as genuine ancestors of MSCs [10, 11]. In addition, they might be considered the 
precursors of microvascular pericytes [13, 34], although more work has still to be done in 
order to clarify the embryological origin and developmental hierarchy of all the mentioned 
cells. 
Our group has demonstrated and then confirmed the great regenerative properties of human 
saphenous vein-derived APs in animal models of limb ischemia [11, 35, 36] and acute 
myocardial infarction (MI) [33, 37]. 
Finally, cells with similar characteristics have been identified also in the intimal sub-
endothelium of the aorta and the saphenous vein [38], where they have been associated with 
the pathogenesis of atherosclerosis (see chapter 7). 
2.3 How to identify pericytes? 
Despite the increasing number of Investigators being focused on perivascular cells, no single 
marker able to unequivocally recognize these cells has been found so far, making the 
identification of pericytes still a challenge. This difficulty comes from the evidence that 
perivascular cells share several markers with other vascular resident cells, which are mainly 
MSCs but also SMCs and ECs [13, 39]. The colocalization inside vascular and perivascular 
niches and the similar morphology shown in in vitro cultures represent the reasons why for 
long time pericytes have been confused with MSCs; while the perivascular localization and 
the expression of smooth muscle alpha actin (−SMA) easily confound pericytes with SMCs. 
In addition, the in vitro culture and expansion of cells may induce changes in the expression 
of some markers, making the characterization of any cell population even harder. For 
example, human CD34pos, CD31/CD146neg pericytes have shown to down-regulate the 
expression of CD34 during the expansion [9, 11].  
To date, the best identification of perivascular cells comes from a combination of criteria 
including the morphology, the anatomical localization in situ, the antigenic profile meant as 
the coexpression of two or more markers, the functional properties and the gene/protein 
expression pattern [22, 40].  
The best confirmation of the nature of expanded cultures of pericytes comes from functional 
assays in vitro, which allow to distinguish pericytes from cells phenotypically similar such as 
MSCs [41]. A common functional test is the angiogenic cooperation with ECs, assessed with 
a matrigel assay in which pericytes promote and stabilize the formation of tubes made of ECs 
[11, 40]. Moreover, the assessment of cell-to-cell communication between pericytes and other 
vascular cells through the establishment of gap junction – commonly Connexin-43 – has been 
proposed as a test able to identify pericytes [42]. Also, the assessment of ALP enzymatic 
activity and the expression of pro-coagulatory components such as the tissue factor and the 
prothrombinase have been indicated as markers of the status of pericyte [42].  
3. The cardiac pericyte 
For long time several lines of investigations have been centred on the physiopathological role 
of pericytes in organs such as the retina, the kidney and the brain, while only recently an 
increasing interest has being shifted also to the heart. In fact, the recognition of the important 
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role of pericytes in cardiac homeostasis and physiopathology has induced more Investigators 
to focus on this cell type. This interest is further justified if we consider that pericytes are cells 
particularly abundant into a big demanding organ extensively vascularised like the heart. CPs 
play a central role in the organ homeostasis because they act as intermediate cells connecting 
the blood system and the vascular endothelium on the one side and the interstitial cells and 
cardiomyocytes on the other side.  
 
 
 
Figure 2: Perivascular cells in the postnatal human heart. Cartoon showing CD34+/CD31-/NG2+ 
microvascular pericytes and advential pericyte-like progenitors in the human neonatal heart. Images 
have been obtained from immunofluorescence staining of sections of myocardial tissue followed by 
confocal microscopy. Endothelial cells positive for the marker CD31 and/or CD34 line the lumen of 
both the capillary and the arteriole. The microvascular pericytes surround the capillary, while the 
adventitial pericyte-like cell is localized within the tunica adventitia of the arteriole. Vascular SMCs 
within the tunica media are recognized by the positivity to NG2. Images have been reproduced with 
permission of JAHA and taken from the original article in [9]. 
 
 
So far, only few populations of CPs deriving from the foetal and postnatal human heart have 
been expanded in vitro and extensively characterized. In 2011, Nees and colleagues have 
purified microvascular pericytes from the ventricular myocardium of adult explanted hearts 
[42]; in their work, Authors used a Percoll density-gradient centrifugation in order to select 
the population of interest after the enzymatic digestion of the tissue. Cultured pericytes were 
recognized by the expression of NG2, PDGFR-, Connexin-43, -SMA and Calponin; 
moreover they showed high expression of tissue factor and ALP activity. The morphology of 
the cells was the typical one of perivascular cells [42]. Later, at the beginning of 2015, the 
group of B. Péault identified a population of heart pericytes in myocardial samples from both 
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foetuses at 17-23 weeks of development and post-mortem adults [15]. Phenotypically, the 
expanded cells are NG2/PDGFR-/CD146pos but CD34/CD45neg; they are able to differentiate 
into cells of the mesodermal lineage, including a limited capacity to generate cardiomyocyte-
like cells both in vitro and in vivo in a mouse model of MI [15]. In the same period, our group 
has identified a population of microvascular pericytes and APs CD34/NG2/PDGFR-pos but 
CD31/CD45/CD146neg in myocardial leftovers from neonates undergoing corrective surgery 
for congenital heart defects (Fig. 2) [9]. After expansion in vitro, cells down-regulate the 
expression of CD34, as we already reported previously in pericytes isolated from the 
saphenous vein [11]. Our CPs express also stemness markers (NANOG, OCT4 and SOX2), 
are clonogenic and show a marked plasticity toward the vascular SMC lineage, while being 
unable to originate electrically competent cardiomyocytes. Importantly, we showed that CPs 
are able to support the angiogenic activity of ECs in an in vitro angiogenic assay and are 
characterized by a secretome enriched with pro-angiogenic factors [9].  
3.1 Epicardial pericytes are coronary SMCs progenitors 
Recently Volz and colleagues used methods of clonal analysis and lineage tracing to elegantly 
demonstrate that epicardial pericytes in the mouse heart are progenitors of coronary artery 
SMCs [43]. Epicardial pericytes migrate to the myocardium during the coronary artery 
development and populate the coronary microvasculature; here, they participate to arterial 
remodelling. Specifically, in correspondence of the sites of vascular formation and 
remodelling close to the aorta, the arterial blood-flow induces Jagged-1 expression in the 
coronary cells. The crosstalk between the pericyte and the EC of the developing coronary 
vessel involves Notch3/Jagged-1 signalling. In response to Jagged-1, CPs upregulate Notch3 
and differentiate into SMCs. Absence of arterial maturation in Notch3-null mice showed that 
Notch3 signalling is required for the pericyte-to-SMC transition [43]. In the adult heart, 
epicardial pericytes that are ancestors of SMCs and that take part in arterial remodelling have 
been identified as PDGFR-/Notch3/NG2pos but PDGFR-neg cells [43]. 
3.2 Ontogeny of cardiac pericytes 
The developmental origin of the pericyte is still a sort of mystery, since the lack of absolute 
markers specific for pericytes has limited the studies of genetic fate tracing. However, some 
important information on the ontogeny of cardiac pericytes have been collected from studies 
with transgenic animal models.  
The origin of perivascular cells in the heart can be traced back to epicardial mesothelial cells. 
A lineage analysis work by Cai and colleagues demonstrated that, in mice embryonic hearts, 
epicardial cells expressing the T-box transcription factor Tbx18 undergo epithelial-to-
mesenchymal transition (EMT, a process crucial during early stages of embryo development 
[44]) and then invade the heart, where they give rise to fibroblasts and vascular mural cells, 
including both pericytes and SMCs coexpressing PDGFR; interestingly, ECs are Tbx18neg, 
suggesting a different evolution [45]. At the same time, a study performed in mice with 
epicardial deletion of PDGFR- demonstrated the importance of the PDGFR--
phosphoinositide 3’-kinase (PI3K) axis signaling for the epicardial cells migration [46]. 
However, this study showed that mural cells develop also from a non-epicardial origin, 
although still dependent on PDGFR- signaling [46]. In addition, PDGFR- is required for 
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the epicardial cell EMT [47]. Finally, the Wilm tumor suppressor 1 (Wt1)/Wnt/-catenin 
signaling pathway is another important axis able to promote the epicardial EMT, ensuring the 
correct cell spindle orientation and stabilizing the adherens junctions [48, 49].  
4. Cardiac pericytes signaling and crosstalk with neighboring cells help 
to preserve heart physiology 
Pericytes within the heart participate in many processes regulating cardiac homeostasis. 
Phenomena such as angiogenesis, the regulation of blood flow, vascular maturation and 
permeability, delivery of trophic substances from the systemic circulation into the myocardial 
interstitium, and the regulation of the coagulatory process are only some of the multiple 
functions attributable to pericytes (illustrated in Fig. 3) Some aspects related with these 
mechanisms are summarized below.  
 
 
 
 
Figure 3: Cartoon summarizing the functions of cardiac pericytes in the physiological and pathologic 
ischemic heart. For details and explanation, see chapter 4 and 5. Abbreviations: CM, cardiomyocyte; Diff, 
differentiation; ECs, endothelial cells; ECM, extracellular matrix; MMPs, metalloproteinases; MSCs, 
mesenchymal stem cells; MyoFb, myofibroblast.  
 
4.1 Angiogenesis, regulation of vessel maturation and permeability 
Pericytes are crucial regulators and stabilizers of angiogenesis and vessel permeability, with 
the physical or paracrine interaction between ECs and pericytes playing a primary role in this 
process. When required, pericytes undergo the transition from a quiescent to the angiogenic 
state, which involves multiple changes in pericytes and the modifications in the contact with 
ECs: pericyte migration and proliferation, cell maturation, coverage of ECs, presentation of 
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growth factors and modulation of extracellular matrix [22, 39]. On the other side, EC viability, 
proliferation and angiogenic activity are regulated. In general, independently from the organ, 
the interaction between the pericyte and the EC is regulated by the crosstalk between some 
ligands/receptors, the main of which are Angiopoietin-1 (Ang1)/Tie2, transforming growth 
factor- (TGF-)/ALK-1/5, Vascular Endothelial Growth Factor A (VEGFA)/VEGFR2, 
PDGF-BB/PDGFR-, N-Cadherin/N-Cadherin, Jagged1/Notch (Fig. 4). Ligands can be either 
soluble (released by cells) or exposed onto the cell membrane. The Table 1 summarizes the 
processes regulated by each molecular interaction. 
 
 
 
Figure 4: Cartoon summarizing the most characterized molecular interactions occurring between ECs and 
pericytes. Ligands can be soluble (paracrine factors) or presented on the cell membrane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of the processes favoring angiogenesis regulated by the main physical or paracrine 
interactions between ECs and pericytes.   
 
 
Also, it has been documented that pericytes can bridge the temporary gaps created between 
two sprouting EC segments, in this way supporting the angiogenic process [57]. However, the 
concept of pericytes being vascular stabilizers has been questioned. Bodnar and colleagues 
showed that human skeletal muscle pericytes do not support the angiogenic process, rather 
Ligand/Receptor Process regulated Ref 
Ang1/Tie2 Vessel stabilization (anti-leak) [50] 
TGFβ/ALK-1/5 
EC proliferation and migration (ALK-1) 
Vessel maturation (ALK-5) 
[51] 
PDGF-BB/PDGFR-β 
Pericyte recruitment and proliferation  
Vessel stabilization  
[52] 
[50] 
VEGFA/VEGFR2 
ECs survival 
Vessel stabilization  
Angiogenesis sprouting 
[53] 
[53] 
[54] 
N-Cadherin/N-Cadherin 
Pericyte recruitment 
Vessel maturation 
[55] 
Jagged1/Notch 
Vessel maturation and stabilization 
Angiogenesis sprouting 
[56] 
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causing a regression of the endothelial tubes formed in an in vitro matrigel assay; the 
mechanism described involves the activation of μ-calpain – protease responsible for the 
cleavage of integrins - induced by the interaction between the CXC chemokine receptor 3 
(CXCR3) expressed on ECs membranes and its ligand produced by pericytes [58].  
The recruitment of pericytes to the developing vasculature is an important step in blood vessel 
maturation [59]. The receptor tyrosine kinase TrkB expressed on the surface of pericytes 
plays an important role in vessel maturation; the ligand for TrkB is the brain-derived 
neurotrophic factor (BDNF), produced by ECs. The signalling downstream BDNF/TrkB is 
critical for the the correct development of the endothelial-pericyte barrier, as demonstrated by 
studies in TrkB deficient mice, which show a reduced pericytes coverage of the cardiac 
microvasculature, an abnormal endothelium and increased vascular permeability [59]. 
In addition to the common microvascular pericytes, CPs have been identified also around the 
pre-capillary arteriolar and post-capillary venular walls, instead of the expected vascular 
SMCs, sites in which they play a crucial role in the regulation of the blood flow [60]. 
Different properties are attributed to these cells. While around arterioles pericytes are 
numerous and embedded in a thick ECM whose function is the maintenance of the vascular 
wall tightness, the venular pericytes are less abundant, fragile and characterized by a weakly 
developed ECM [60]. Cross-talk between ECs and pericytes in both coronary pre-capillary 
arterioles and post-capillary venules is crucial for the maintenance of vascular wall tightness 
and regulation of permeability [61].   
4.2 Trophic functions 
In addition to the trophic support for ECs common to all pericytes, an important function of 
CPs might be the regulation of the barrier endothelial cells-pericytes and pericytes-ECM 
allowing the flux of nutritive substances - such as the fatty acids required for the demanding 
cardiomyocyte metabolism - from the circulating blood into the interstitium, and thus to 
cardiomyocytes. In order to overcome the hydrophobic ECM, pericytes processes pass 
through the ECM and build connections with other interstitial cells through gap junctions.  
4.3 Production of pro-coagulatory substances  
Pericytes are the only cells in the vascular wall producing tissue factor [62]; moreover, they 
produce prothrombinase [42]. Arteriolar and coronary artery pericytes control coagulatory 
processes by incorporating and storing tissue factor and prothrombinase at high levels in their 
plasmalemma and ECM; instead, venular pericytes produce less amounts of the substances 
above in physiological conditions but significantly upregulate their expression when an 
inflammation occurs [42]. 
5. Healing potential of local pericytes in the ischemic heart  
Ischemic heart disease is characterized by a reduced blood supply to the cardiac muscle. One 
of its severe manifestations, the acute MI, is characterized by the sudden occlusion of a 
coronary artery; the consequence is an acute loss of blood flow to a region of myocardium, 
resulting in a massive necrosis of myocytes. The infiltration of circulating inflammatory cells 
and the proliferation of myofibroblasts promote the reabsorption of the necrotic tissue, which 
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is gradually substituted by “reparative fibrosis”, important to preserve the structure of the 
heart although at the expense of an increase in stiffness. The final effect is a change in the 
shape and architecture of the left ventricle that usually becomes more dilated, process named 
adverse ventricular remodelling. If this process becomes uncontrolled and persistent over time, 
the function of the heart as a pump will be impaired, finally bringing to a global failure of the 
whole organ [63].    
In the contest of a MI, what we need are: 1) the substitution of necrotic areas with fibrotic 
tissue (process called “repair”), in order to preserve the structural integrity of the organ and 2) 
the revascularization of the damaged areas of myocardium, since without perfusion of blood 
bringing oxygen and trophic factors no vital tissue can grow. In later stages, 3) ideally the 
fibrotic tissue should be degraded and lost cells be replaced by new functional cells (process 
named “regeneration”). Given their pleiotropic properties, pericytes might be able to address 
all these purposes in the ischemic heart, from the organ repair to its later regeneration (Fig. 3). 
How do pericytes work? Starting from the first point, pericytes can directly differentiate into 
myofibroblasts producing reparative fibrosis that can contribute to the preservation of the 
ventricular structure in early phases post-MI. This process implements the repair through 
granulation that occurs thanks to tissue macrophages.  
For the revascularization, CPs can recruit ECs to the site of injury by paracrine mechanisms; 
the physical cooperation between CPs and ECs is crucial to instruct ECs to organize in 
vascular structures, favouring the angiogenic process. In addition, pericytes can attract and 
recruit other pericytes, amplifying the reparative process. The documented ability of CPs to 
differentiate into vascular SMCs [9, 43] may also promote arterial collateralization, term 
indicating the formation of new alternative vascular branches that overcome the point of an 
artery obstruction and perfuse the downstream myocardial tissue. This event is important in 
the peri-infarct myocardium, since the arteriogenesis boosts the reperfusion of ischemic zones.  
With regard to the last point listed above, scar remodelling and tissue regeneration, CPs might 
release tissue metalloproteinases able to degrade the fibrous matrix, as it has already been 
demonstrated in other organs. Ideally, for the optimal healing of the ischemic heart it would 
be crucial that the degradation of the fibrotic scar was followed side-by-side by the generation 
of new cardiomyocytes and other stromal cells. Although this process is not sufficient in case 
of extensive injury, the cardiomyogenic ability of CPs has recently been documented [15]. 
Given the abundance of microvascular pericytes in the heart compared with other cardiac 
stem cells (CSCs), the cardiomyogenic and vasculogenic contribution of resident CPs might 
be the key for the resolution of limited damages post-ischemia, especially in non-severe forms.  
Last, the supposed role of precursors of MSCs attributed to vascular pericytes [64] underlines 
once again the importance of these cells in ischemic situations, given the need of various 
populations of progenitor cells with different lineage commitment for the repair of the 
functionally complex heart tissue.  
6. Therapeutic effect of pericytes transplantation in preclinical models of 
myocardial infarction  
Pericytes are gaining an increasing interest for application in cardiovascular regenerative 
medicine due to their pleiotropic properties and strong angiogenic capability; the reasons for 
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using these cells are several. Importantly, first of all pericytes are safe cells, since they 
overcome the teratogenic risk associated with pluripotent stem cells; however, despite 
preclinical studies have not raised concerns regarding side effects of pericytes, a systematic 
tumorogenesis investigation needs to be done before starting clinical trials according to 
international guidelines. Then, their rich secretome is composed of cytokines and growth 
factors able to stimulate the process of tissue regeneration and angiogenesis by paracrine 
mechanisms, and of chemoattractant molecules able to recruit further cells to the site of injury. 
Moreover, the relative abundance of pericytes can be an advantage when choosing the best 
cell type to use for cell therapy. As an example, microvascular CPs are much more abundant 
than other classes of stem or progenitor cells in the heart; as a consequence, the process of 
isolation and expansion of pericytes from small cardiac biopsies might be easier than the 
derivation of classical CSCs. At this regard, we demonstrated the feasibility and high 
reproducibility of deriving CPs, then expanded to several millions, starting from tiny 
myocardial leftovers weighing only less than 100 mg, obtained from new-borns undergoing 
corrective surgery for congenital heart defects [9]. A further advantage of using pericytes for 
cell therapy applications might derive from the supposed immune-privileged nature of the 
cells; if confirmed true, this factor will support and favour the allogeneic transplantation when 
the urgency to receive the cell therapy does not allow enough time for the autologous 
approach.  
The cell therapy approach is based on the isolation and expansion in vitro of pericytes to 
reach a number sufficiently high for autologous cell therapy into the same patient. At this 
purpose, on the one side pericytes deriving from extra-cardiac sources might be preferred for 
the easy accessibility to peripheral tissues, and have been already used in animal models of 
ischemic heart disease. On the other side, however, pericytes deriving from the heart might be 
endowed with higher plasticity and commitment versus all the cardiovascular lineages.  
6.1 Preclinical studies with non-cardiac pericytes 
A limited number of studies performed recently have tested the therapeutic activity of non-
cardiac pericytes in preclinical models of MI, but this field is intended to grow quickly in the 
upcoming years. In all the studies reported below, the major benefits of pericytes are 
attributable to their paracrine activity rather than to a direct trans-differentiation into 
cardiovascular cells or the fusion with resident cardiac cells. The first application can be 
traced back to 2011, when our group demonstrated the great regenerative ability of human 
saphenous vein derived pericyte-like progenitors (SVPs) in both an immunocompetent and 
immunodeficient mouse model of MI [33]. When delivered in the peri-infarct area, SVPs 
were able to improve the indexes of cardiac function and contractility, to reduce the size of 
the fibrotic scar and to stimulate angiogenesis compared with control mice not receiving cell 
therapy. The mechanistic pathway is based on the microRNA-132, constitutively released by 
SVPs but further upregulated under hypoxia; importantly, microRNA-132 reduces the 
differentiation of fibroblasts into myofibroblasts, through the inhibition of Ras-GTPase 
activating protein and methyl-CpG-binding protein 2, thus exerting a protective action from 
fibrosis [33]. The peculiar resilience of SVPs to oxidative stress [36] may promote 
angiogenesis in the infarcted ventricle. Two years later, Chen and colleagues tested the 
regenerative ability of human microvascular skeletal muscle pericytes in an immunodeficient 
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mouse model of MI [65]. Intramyocardial transplantation of CD146 pos, CD34/CD45/CD56neg 
pericytes improved left ventricular function and angiogenesis, while attenuating myocardial 
fibrosis and the infiltration of inflammatory cells into the site of injury, compared to controls 
[65]. In the same year, Yannarelli and colleagues evaluated the reparative ability of human 
umbilical cord perivascular cells in an immunodeficient mouse model of MI [66]. Similarly to 
the previous studies, pericytes improved indexes of cardiac contractility; however, no 
improvement was observable with regard to infarct size in comparison with control mice [66].  
6.2 Preclinical studies with cardiac pericytes 
The first preclinical study with CPs was published only recently, at the beginning of 2015, 
from the group of Bruno Péault [15]. Contrary to cells sourced from other tissues, a 
subpopulation of CPs (already described in chapter 3) was able to generate new cardiac 
Troponin I and T and Connexin-43pos cardiomyocytes when injected either in infarcted 
ventricles of immunodeficient mice or in healthy animals, demonstrating their 
cardiomyogenic potential [15]. Once again, it might be possible that pericytes deriving from 
the heart are more committed toward a cardiogenic process. But this needs still to be 
demonstrated given pericytes heterogeneity. For example, given their vasculogenic properties, 
CPs might be the ideal candidate for vascular application within the heart as compared with 
pericites from other organs. Furthermore, our studies show that cardiac pericytes do not have 
spontaneous electrical activity and therefore it is unlikely that once transplanted into the heart 
they will trigger arrhythmias [9].  
6.3 Combinatorial cell therapy 
Another intriguing possibility to reach better results in terms of cardiac regeneration is the 
combinatorial cell therapy, consisting in the simultaneous delivery of multiple cell types to 
improve the processes of cardiomyogenesis and vasculogenesis in the injured heart. A study 
of this kind was recently performed by our team [37]. The combined intramyocardial delivery 
of human SVPs and cKitpos CSCs in an immunodeficient mouse model of MI resulted in the 
enhancement of the cell therapeutic activity in comparison with the cell populations delivered 
in single therapy. In fact, in our model SVPs and CSCs additively work to reduce the infarct 
size and to stimulate vascular proliferation and arteriogenesis in the infarcted left ventricle, 
although cardiac function did not show a further improvement compared with the effects of 
the single cell populations [37].  
6.4 Limitations and future studies 
Although positive and encouraging results have been obtained with the above preclinical 
models of MI, the limitation of these studies is represented by the use of immunodeficient 
mice, in which the immune system is compromised and thus leaves space to questions and 
doubts on the real therapeutic activity of cells when translated into a clinical scenario. 
Considering this point, it is clear that further studies with pericytes in large animal models of 
MI, for which the physiological anatomy of the cardiovascular system is much closer to that 
of humans, are required before proceeding with any clinical trial. This will be the next 
challenge. In the meanwhile, moving toward a clinical translation of pericyte products, our 
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team has optimized a standard operating procedure for the production of clinical grade SVPs 
for application in patients with refractory angina [67].    
7. Pericyte dysfunction and implication in cardiovascular diseases 
Cells are receptive elements that actively respond to changes in the physiological environment 
in which they reside; chemical or mechanical stimuli can perturb cell behaviour and trigger 
particular intracellular pathways resulting in local or systemic phenomena. These responses 
can be positive but also injure the organism. Also for CPs, despite the marked healing 
properties described above, a perturbation of the cell physiological behaviour can activate 
quiescent mechanisms and transform cells in dangerous elements participating in the 
pathogenesis of cardiac diseases. Molecular programs regulating these dual fates of pericytes 
are yet unknown, but it is reasonable that different subtypes of pericytes might be involved. 
The multiple functions of CPs and the wide number of biological processes in which they are 
involved might even favour this negative transformation, through exposure of cells to 
different stressful stimuli. 
When activated, dysfunctional pericytes may differentiate into chondrocytes, osteocytes, 
macrophages and myofibroblasts, contributing to the onset of phenomena such as 
atherosclerosis, fibrosis and vascular calcification (Fig 5). As follows, we report on the main 
findings relative to these mechanisms. 
 
 
Figure 5: Cartoon summarizing the contribution of dysfunctional pericytes in the pathogenesis of 
cardiovascular diseases. 
 
7.1 Thrombosis and atherosclerosis 
The intra-operatory preparation of explanted saphenous veins before coronary artery bypass 
surgery requires the non-pulsatile flushing of the vein with various types of saline solutions, 
procedure that causes the de-endothelialization of up to 75% of the total endothelial surface; 
this situation triggers coagulatory processes involving the release of tissue factor and 
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assembling of prothrombinase in the subendothelium. This protocol has been indicated as 
responsible for the failure of the bypass graft [68]. Indeed, a contribution of macrovascular 
intimal pericytes in the pathogenesis of atherosclerosis, thrombosis and saphenous vein graft 
failure has been described. Juchem et al. identified a population of pericytes expressing high 
concentrations of tissue factor in the sub-endothelium of the aorta and the saphenous vein, 
coupled with ECs of the luminal intima [38]. Importantly, these pericytes were found within 
atherosclerotic plaques and coronary vein grafts stenosis, in which were responsible of the 
intima thickening and represented more than the 90% of proliferating cells. The exposure of 
endothelium-denudated venous grafts to circulating serum provoked a significant increase in 
the amount of tissue factor (up to 25-folds in 1 hour in in vitro tests), highlighting a potent 
pro-coagulatory and pro-thrombogenic ability for intimal pericytes [38]. In healthy vessels, 
however, the intact luminal endothelium exerts a physiological protective and preventive 
function, neutralizing the tissue factor through the system thrombomodulin-protein C and 
avoiding the occurrence of thrombosis [38].  
A mechanism responsible for the recruitment of pericytes to the site of the developing 
atherosclerotic lesion could involve the PI3K/Akt axis activated by the binding of the 
hepatocyte growth factor (HGF) to its receptor c-Met on the surface of pericytes [69]. 
Although this mechanism has been described in femoral arteries, it is possible that the same 
pathway is involved in the heart, where HGF is produced by human aortic ECs and vascular 
SMCs [70]. T-cadherin, a unique member of the cadherin family of adhesion molecules 
highly expressed in the aorta, is another factor implicated in the atherosclerotic process. An 
analysis of this factor in normal human aorta and atherosclerotic lesions showed that T-
cadherin is expressed by ECs, SMCs and pericytes in the aortic intima and media, and in the 
walls of vasa vasorum and pericytes in the adventitia. Noteworthy, its expression in SMCs 
and pericytes correlates with the severity of the lesion, with higher levels of T-Cadherin 
corresponding to more severe stages of atherosclerosis [71]. Last, in the human 
atherosclerotic coronary artery, a mutation in low-density lipoprotein (LDL) receptor-related 
protein 6 causes early atherosclerosis; this mutation co-localizes with the PDGFR-β in 
vascular SMCs and induces cell proliferation in response to PDGF stimulation [72]. Given the 
high expression of PDGFR-β in pericytes, it is likely that this pathway might be triggered by 
PDGF also in these cells. 
7.2 Ischemia/reperfusion injury 
Studies performed with a mouse model of cardiac ischemia-reperfusion injury have 
demonstrated that microvascular pericytes are responsible for the occurrence of endothelial 
dysfunction with a mechanism involving the neurotrophine receptor p75NTR [73]. This 
mechanism would work also in human subjects. During ischemia, cardiomyocytes rapidly 
increase the secretion of pro-Nerve Growth Factor, which binds to the p75NTR on the surface 
of PDGFR- pos pericytes and this results in a modification of pericytes architecture including 
a reduction of vascular coverage and a shortening of cell processes, finally disrupting the 
endothelial cell-pericyte interaction and provoking an increase of vascular permeability; the 
cardiomyopathy becomes lethal in adult mice [73].  
Another phenomenon involving pericytes occurring in ischemic patients is the coronary no-
reflow, described as the failure to achieve adequate reperfusion of the cardiac 
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microcirculation after the reperfusion that follows a coronary artery obstruction. It represents 
a common complication of the reperfusion procedure. Because of constriction mechanisms, 
cardiac pericytes have been identified as responsible for the failed coronary capillaries 
reperfusion [74]. 
7.3 Calcific vasculopathy  
One possible mechanism responsible for the chondrogenic differentiation of pericytes, 
described in retinal pericytes, involves the Wnt/-catenin signalling [75]. Pericytes express 
several Wnt receptors, among which there are the LDL receptor-related proteins 5 and 6 and 
some receptors of the Frizzled family. TGF-3 is an activator of the Wnt/-catenin pathway, 
which induces the expression of the chondrocyte marker SOX-9 and the accumulation of 
collagen and glycosaminoglycan into the pericyte matrix [75]. Importantly, in the heart SMCs, 
macrophages and foam cells within aortic atherosclerotic plaques produce high levels of TGF-
3 [76], thus this mechanism might promote the aortic calcification. Another factor associated 
with the osteogenic differentiation of pericytes is the Vascular Calcification Associated Factor 
(VCAF), detectable in arterial calcified lesions but not in noncalcified arteries, and highly 
expressed during the osteogenic differentiation of pericytes in vitro. Interestingly, VACF has 
been described as a protective factor in pericytes, since its knockdown resulted in accelerated 
mineralization in vitro and increased formation of calcific nodules [77]. VACF could be 
upregulated as a defence mechanism against vascular calcification. SMCs, ECs, macrophages 
and osteoblasts within femoral calcified arteries would be the cells responsible for VACF 
production [78]. Although this factor has been investigated in femoral arteries, we can 
suppose that a similar mechanism might regulate the evolution of calcific lesions into cardiac 
arteries.  
7.4 Fibrosis 
The role of pericytes in myocardial fibrosis and perivascular fibrosis has not been elucidated 
yet. Despite the cellular origin of myofibroblasts has been unclear for many years, we 
presently know that perivascular cells might differentiate into myofibroblasts [79]. What is 
known is that cardiac pericytes produce proteins of the ECM [42]. As said above (chapter 5), 
substitutive fibrosis can be beneficial to the organ after a MI occurs; however, if this process 
becomes uncontrolled, the persistent deposition of interstitial fibrosis and increase in 
ventricular wall stiffness will be detrimental for the global heart function.  
In the mouse heart Gli1pos perivascular adventitial cells have been identified as precursors of 
myofibroblasts and indicated as responsible for heart fibrosis after an injury, finally leading to 
heart failure [80]. The genetic ablation of Gli1pos cells was able to rescue the organ function, 
suggesting that this subpopulation of perivascular cells might be the therapeutic target for the 
prevention of organ dysfunction [80]. In heart failure, galectin-3 released by inflammatory 
macrophages activates, in a paracrine fashion, other macrophages, fibroblasts and pericytes; 
the result of this stimulus is the production of pro-collagen I, which is finally converted into 
the mature and cross-linked forms contributing to myocardial fibrosis [81].  
Another work showed that in a mouse model of Duchenne muscular dystrophy the 
accumulation of severe coronary perivascular fibrosis is caused by a population of adventitial 
Sca1/PDGFR- pos, CD31/CD45neg cells producing high levels of Collagen type I in response 
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to TGFβ1 signalling [82]. Wu and colleagues published similar results, demonstrating that 
adventitial perivascular Sca1pos cells residing in the murine aorta contribute to the fibrotic 
remodelling in hypertension [83].   
However, contrasting results have been obtained. Recently, Birbrail et al. demonstrated that 
Nestin/NG2 pos pericytes significantly accumulates in the mouse infarcted area post-MI; 
however, these cells do not produce type I Collagen and thus do not contribute to the 
formation of the fibrotic scar. Collagen was instead produced by NG2neg cells [84]. In support 
of this evidence, our group reported that NG2pos pericytes isolated from the human saphenous 
vein and injected intra-myocardially in the site of injury in a mouse model of MI are 
protective against fibrosis (see chapter 6) [33]. 
8. Conclusion 
Despite the recognized biological potential of pericytes and APs residing in the heart, so far 
these cells have been under-investigated in applications for cardiovascular therapy and 
regeneration. But the current research is paving the way for future studies. Also, both the 
crucial involvement of pericytes in the control of cardiac physiology and the contribution of 
dysfunctional pericytes to pathological conditions of the heart are elements underlining the 
need to focus more on this population of cells, since new mechanistic insights might derive 
from the knowledge of the biology of CPs and, as a consequence, new therapeutic approaches 
might be developed for cardiac diseases.  
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